On April 1, 2026 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, reported the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnerships, and reflects the continued promise of our tumor-activated platforms," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "The nomination of a development candidate highlights our ability to translate platform insights into differentiated therapeutics in collaboration with leading oncology companies."
"We are pleased to reach this important milestone with Bristol Myers Squibb, which reflects strong collaboration between our teams and the disciplined execution of our research and development efforts," said Janeen Doyle, Chief Corporate and Business Development Officer of Janux. "Advancing a program to development candidate nomination represents a key step toward IND-enabling studies and clinical development."
Under the terms of the collaboration agreement, Janux is responsible for conducting preclinical development through IND submission. Bristol Myers Squibb will hold the IND and will be responsible for subsequent clinical development and global commercialization of products arising from the collaboration. Janux will remain actively involved in the program, supporting Bristol Myers Squibb through completion of the first Phase 1 clinical study.
In addition to the $35 million milestone payment associated with development candidate nomination, Janux is eligible to receive additional development, regulatory and commercial milestone payments, as well as tiered royalties on global product sales.
(Press release, Janux Therapeutics, APR 1, 2026, View Source [SID1234664140])